Free tool
FAERS Monitor: Rydapt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207997 or its brand name (Rydapt, Midostaurin). Reports on generic versions are filed under their own applications.
Reports
1,957
Serious
1,424
73% of reports
Hospitalization
506
Death reported
472
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death329
- nausea166
- vomiting105
- drug ineffective100
- acute myeloid leukaemia recurrent93
- pancytopenia93
- pyrexia91
- diarrhoea90
- febrile neutropenia78
- bone marrow failure76
- drug intolerance73
- lymphadenopathy60
- platelet count decreased57
- skin toxicity57
- malignant neoplasm progression53
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 182 |
| 2018 | 299 |
| 2019 | 342 |
| 2020 | 365 |
| 2021 | 280 |
| 2022 | 160 |
| 2023 | 148 |
| 2024 | 84 |
| 2025 | 37 |
| 2026 | 60 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,202 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute myeloid leukaemia recurrentSignal | 93 | 486.6 | 397.2 | 42,658 |
| skin toxicitySignal | 57 | 109.5 | 84.7 | 5,961 |
| bone marrow failureSignal | 76 | 40.3 | 32.4 | 2,869 |
| lymphadenopathySignal | 60 | 18.2 | 14.2 | 961 |
| pancytopeniaSignal | 93 | 17.9 | 14.7 | 1,470 |
| febrile neutropeniaSignal | 78 | 12.7 | 10.2 | 827 |
| drug intoleranceSignal | 73 | 8.1 | 6.5 | 451 |
| platelet count decreasedSignal | 57 | 5.8 | 4.5 | 220 |
| malignant neoplasm progressionSignal | 53 | 5.6 | 4.3 | 195 |
| deathSignal | 329 | 4.1 | 3.7 | 802 |
| pyrexiaSignal | 91 | 2.8 | 2.3 | 107 |
| vomitingSignal | 105 | 2.4 | 2.0 | 86 |
| nauseaSignal | 166 | 2.3 | 1.9 | 119 |
| diarrhoea | 90 | 1.5 | 1.2 | 15 |
| drug ineffective | 100 | 0.8 | 0.7 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.